Disease / condition

AML clinical trials

Free access to 63 studies·10+ countries·Updated daily19 recruiting
63
Total trials
10+
Countries
10+
Sponsors
19
Recruiting
By phase
N/A19
Phase 116
Early Phase 111
Phase 210
Phase 35
By status
Recruiting19
Completed14
Not yet recruit...11
Unknown8
Withdrawn4
Top countries
China26
United States of America6
Spain4
France4
Netherlands4
Top sponsors
Zhejiang Universit...8
Institute of Hemat...4
PETHEMA Foundation4
Beijing Immunochin...2
Nantes University ...2
Recent trials
Latest clinical trials for AML
NCT06399315·Phase 1Recruiting
Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers
Eilean TherapeuticsAustralia
NCT05875649Not yet recr...
A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure
Nanfang Hospital, Southern Med...China
NCT05732688Recruiting
Drug-screening in AML at Relapse for Targeted Treatment
University Hospital Inselspita...Switzerland
NCT05734898Recruiting
NKG2D CAR-NK & r/rAML
Zhejiang UniversityChina
NCT05473221·Phase 1Not yet recr...
Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML
Zhejiang UniversityChina
NCT05467254·Phase 1Not yet recr...
Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML
Zhejiang UniversityChina
NCT05463640·Phase 1Not yet recr...
Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML
Zhejiang UniversityChina
NCT05467202·Phase 1Not yet recr...
Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML
Zhejiang UniversityChina
NCT05388305Recruiting
Universal CAR-γδT Cell Injection in the AML Patients
Hebei Senlang Biotechnology In...China
NCT05339204Recruiting
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission
National Research Center for H...Russian Federation
NCT05287568·Phase 1Recruiting
CC-486 and Venetoclax for Acute Myeloid Leukemia
University of Colorado, DenverUnited States of America
NCT05290662Recruiting
Registry of Patients Having Received oNKord®
Glycostem Therapeutics BVGermany,Switzerland
NCT05256277·Phase 1Not yet recr...
NK Cell Therapy for AML
Zhejiang UniversityChina
NCT05239689·Early Phase 1Recruiting
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies
Zhejiang UniversityChina
NCT05252572·Early Phase 1Recruiting
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies
Zhejiang UniversityChina
jRCT2021210050Recruitment ...
Untitled Trial
Novartis Pharma. K.K.France;Italy;Taiwan;Australia;United States of America;Canada;Korea;Germany;Spain
NCT05199051·Phase 2Not yet recr...
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Centre Antoine Lacassagne
NCT05063123·Phase 2Withdrawn
Study to Assess an Interphase Cycle With Flotetuzumab.
Stichting Hemato-Oncologie voo...Netherlands
NCT05048615·Phase 2Recruiting
Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML
Hospital Universitario Dr. Jos...Mexico
NCT04973618·Phase 1Withdrawn
Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
Aptevo Therapeutics
About this record

Access comprehensive clinical trial information for AML through Pure Global AI's free database. This collection includes 63 clinical trials across multiple phases including N/A, Phase 1, Early Phase 1. Currently, 19 trials are actively recruiting participants.

Research for AML is being conducted in China, United States of America, Spain and 7+ other countries. Leading sponsors include Zhejiang University and Institute of Hematology & Blood Diseases Hospital, China. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.

Pure Global AI provides free access to 63 clinical trials studying AML, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.

The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.

Top research sponsors include Zhejiang University, Institute of Hematology & Blood Diseases Hospital, China, PETHEMA Foundation, among others.